Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: October 2009
-
By Andrew Williams — As many children and partygoers prepare to dress up as the undead for trick-or-treating fun or Halloween-themed parties, the scientific community is taking the potential of a Zombie attack more seriously. A group of mathematicians at the University of Ottawa and Carleton University (also in Ottawa) have prepared a paper…
-
By Donald Zuhn — Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics data exclusivity debate. In view of last week's Time magazine article "How Drug-Industry Lobbyists Got Their Way on Health Care," which mentions…
-
By Donald Zuhn — Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics data exclusivity debate. In view of last week's Time magazine article "How Drug-Industry Lobbyists Got Their Way on Health Care," which mentions…
-
By Kevin E. Noonan — Just when you thought . . . it was safe to ignore patent reform, and fresh off a concerted push from the new Commerce Secretary, the new Patent and Trademark Office Director, and the new Deputy Director for patent reform that includes fee setting and substantive rulemaking authority, a…
-
By Donald Zuhn –– A report in last week's Time magazine focuses on the ongoing debate over "an obscure but crucial health-care provision": follow-on biologics data exclusivity — the period of time that generic biologic manufacturers would have to wait before they are allowed to use an innovator's data to secure FDA approval for…
-
By Suresh Pillai — Teva Loses Bid For Dismissal of Famciclovir Infringement Suit Last week, the U.S. District Court for the District of New Jersey denied Teva Pharmaceutical's bid to have Novartis Pharmaceuticals' patent infringement suit dismissed for lack of plaintiff standing. Novartis and two of its subsidiaries filed the original lawsuit in 2005…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Wyeth v. Intervet Inc. et al.1:09-cv-00780; filed October 20, 2009 in the District Court of Delaware • Plaintiff: Wyeth• Defendants: Intervet Inc. d/b/a…
-
October 26-28, 2009 – Intellectual Property Counsels' Committee (IPCC) Fall Conference & Meeting (Biotechnology Industry Organization) – Washington, DC November 9-10, 2009 – Patent Litigation 2009 (Practising Law Institute) – Atlanta, GA November 9-11, 2009 – Developing IP Strategies for Crystalline Forms*** (International Quality & Productivity Center) – London, England November 10, 2009 – The…
-
By Donald Zuhn –– On Tuesday, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its latest venture funding study. The study, conducted with PriceWaterhouseCoopers and Thomson Reuters, indicates that venture capitalists invested $4.8 billion in 637 deals in the third quarter of 2009,…
-
By Kevin E. Noonan — Bans on gene patenting and the possibility of having a court, Congress, or czar declare them banned are all the rage recently, spurred in part by the lawsuit against Myriad Genetics and the University of Utah (among other defendants) in the Federal District Court for the Southern District of…
Patent Docs 